- Conditions
- Huntington Disease, Chorea, Executive Dysfunction
- Interventions
- 20mg daily citalopram, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1633–1656
of 12,606
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- IR Viloxazine, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more
- Conditions
- Aging, Manual Dexterity, Piano Therapy
- Interventions
- Piano training (Active), Piano Training (Passive)
- Behavioral
- Lead sponsor
- Westminster College
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- New Wilmington, Pennsylvania
- Conditions
- Brain Metastases, Brain Cancer
- Interventions
- 18F-Fluciclovine
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Iron Overload, Hemosiderosis
- Interventions
- Non-contrast MRI
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Huntington's Disease
- Interventions
- Pridopidine, Placebo
- Drug · Other
- Lead sponsor
- Prilenia
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Strength Training, Endurance Training
- Other
- Lead sponsor
- University of Georgia
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Athens, Georgia
- Conditions
- Type 2 Diabetes
- Interventions
- phone application, Standard of Care (SOC)
- Device · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Oakland, California • San Francisco, California
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- LY3361237, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 19
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 16 more
- Conditions
- Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
- Interventions
- PCA plus methadone (Experimental), PCA Alone (SOC)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Mild Cognitive Impairment
- Interventions
- PEP, CCI
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Rochester, New York
- Conditions
- Alcohol Use Disorder
- Interventions
- Alcohol
- Drug
- Lead sponsor
- Jessica Weafer
- Other
- Eligibility
- 21 Years to 26 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Major Depressive Disorder
- Interventions
- Agomelatine, paroxetine, placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • National City, California • Orange, California + 40 more
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
- Interventions
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- NFC-1, Placebo
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Kidney Disease
- Interventions
- Placebo, AST-120
- Drug
- Lead sponsor
- Tanabe Pharma Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,015 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 46
- States / cities
- Tuscaloosa, Alabama • Hot Springs, Arkansas • Bakersfield, California + 43 more
- Conditions
- Malaria
- Interventions
- Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo
- Biological
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
- Interventions
- Acalabrutinib, Investigator's choice of treatment
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode
- Interventions
- L-arginine, L-arginine Loading Dose, Placebo
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Lupus Nephritis
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anxiety, Depression, Stress
- Interventions
- Project THINK, Project SHARE
- Behavioral
- Lead sponsor
- Harvard University
- Other
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Autism Spectrum Disorder, Developmental Delay
- Interventions
- Saliva collection, Vineland Adaptive Behavior Scale-II Assessment
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Months to 6 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- PTSD
- Interventions
- Sudarshan Kriya Yoga, Mindfulness-Based Stress Reduction
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin